- PK Data from Drug-Drug Interaction Study Describes Lack of CYP3A4 Interactions
A mishap in northern Asia would be an awful catalyst even to ponder. But a less apocalyptic one would be oil.
Some investors are disappointed with the timing of Clovis' ovarian cancer maintenance clinical trial.
Tesaro's newly approved PARP inhibitor Zejula is really 50% more expensive than its list price implies.